Alembic Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals reported standalone revenue of Rs. 6,651 crore for FY2026, up ~10.3% from Rs. 6,033 crore in the prior year. Profit After Tax surged to Rs. 503 crore from Rs. 115 crore in the prior year — a jump of ~337% year-on-year, boosted significantly by a Rs. 100.27 crore deferred tax asset recognised due to the Finance Act amendment. The company recorded exceptional items totalling Rs. 66.99 crore for the year, comprising a Rs. 48.64 crore labour code provision and a Rs. 18.35 crore write-down on Sikkim manufacturing assets classified as held for sale. EBITDA margin expanded from 15.74% to 16.82%. The Board recommended a dividend of Rs. 12 per share (600%), up from Rs. 11 (550%) in the prior year. Statutory auditors KKC & Associates LLP issued an unmodified opinion on both standalone and consolidated results.
The sharp PAT growth driven by deferred tax credit is a one-off benefit; underlying operational performance shows steady margin expansion. The Sikkim asset write-down signals ongoing stress at that facility. The increased dividend signals management confidence.